You are here
ORPRO THERAPEUTICS INC
UEI: DMFYKL5PQLF3
# of Employees: 3
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Development of modified human thioredoxin as an inhaled biologic therapeutic for cystic fibrosis
Amount: $224,482.00SUMMARY Effective management of obstructive pulmonary diseases characterized by thickenedhighly viscoelastic mucus represents a significant unmet medical needespecially in cystic fibrosisCFan inherite ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Mucoadhesive drug conjugates for controlled-release inhalation delivery
Amount: $228,370.00SUMMARY Sustained release of drugs delivered onto mucosal surfaces by oraltopical or inhaled routes can be a highly effective means of improving topical bioavailabilityProlongation of epithelial resid ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Development of modified human thioredoxin as an inhaled biologic therapeutic for cystic fibrosis
Amount: $1,499,635.00SUMMARY Effective management of obstructive pulmonary diseases characterized by thickenedhighly viscoelastic mucus represents a significant unmet medical needespecially in cystic fibrosisCFan inherite ...
SBIRPhase II2018Department of Health and Human Services National Institutes of Health -
Development of human thioredoxin as a mucolytic therapy for Cystic Fibrosis
Amount: $183,089.00DESCRIPTION (provided by applicant): Effective management of obstructive pulmonary diseases, especially Cystic Fibrosis (CF), represents a significant unmet medical need. Such diseases are characteriz ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health